“…Indeed, the binding of both active entities allows to increase the bioavailability of the final dual molecule and to merge active molecules with independent modes of action to prevent the emergence of resistance. 25 This dual prodrug strategy has been applied to malaria 20,[26][27][28][29][30][31][32][33][34] and to various other diseases such as tuberculosis, 35 cancer, 36 and HIV. [37][38][39] In particular, combination of two active components targeting the heme detoxification pathway and the thiol network of malaria parasites was shown to provide the proof of concept both in vitro and in vivo, and at the molecular level.…”